Full Press Release Details
TherapeuticsMD Announces Full Year 2024 Financial
BOCA RATON, Fla.--(BUSINESS WIRE)-March
27, 2025 -- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights
to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024.
Full Year 2024 Financial Results
Net Loss from Continuing Operations
License and Service Revenues from Continuing
Total Operating Expenses from Continuing Operations
Evaluation of Strategic Alternatives
About TherapeuticsMD
TherapeuticsMD was previously a women's
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily
collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may
contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's
objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited
to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a
review process as well as statements, other than historical facts, that address activities, events or developments that the company intends,
expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such
as "believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience
and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise
any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important
factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are
described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the
following: whether the company's licensees will be successful at commercializing the products that they licensed and acquired from
TherapeuticsMD; whether the company is successful in winding down its operations and the costs associated therewith, including the company's
ability to obtain any additional financing necessary therefor and any adjustments to the net working capital purchased as part of the
Mayne Pharma transaction; whether the company is successful in identifying strategic pathways to create additional shareholder value;
the company's ability to remain listed on Nasdaq; the impact of product liability lawsuits; the impact of leadership transitions;
the impact of Mayne Pharma Group's agreement to be acquired by Cosette Pharmaceuticals, Inc. and the volatility of the trading price
of the company's common stock.
Chief Executive Officer
In-Site Communications, Inc.
Source: TherapeuticsMD, Inc.